Table 1.
Summary of the number of infliximab- and adalimumab-derived peptides and clusters identified by MAPPs using Sepharose or FG magnetic beads.
| VH region |
CH region |
VL region |
CL region |
Total |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infliximab and Adalimumab | LC gradient time (h) | Cluster | Peptide | Cluster | Peptide | Cluster | Peptide | Cluster | Peptide | Cluster | Peptide | |
| Infliximab | ||||||||||||
| Donor 1 | Sepharose | 1 | 2 | 23 | 1 | 2 | 0 | 0 | 3 | 15 | 6 | 40 |
| |
FG magnetic |
1 |
2 |
28 |
2 |
4 |
0 |
0 |
3 |
19 |
7 |
51 |
| Donor 2 | Sepharose | 1 | 1 | 7 | 0 | 0 | 0 | 0 | 1 | 5 | 2 | 12 |
| |
FG magnetic |
1 |
2 |
5 |
1 |
2 |
1 |
1 |
2 |
17 |
6 |
25 |
| Adalimumab | ||||||||||||
| Donor 3 | Sepharose | 1 | 2 | 24 | 0 | 0 | 2 | 3 | 1 | 7 | 5 | 34 |
| 2 | 3 | 30 | 0 | 0 | 3 | 6 | 1 | 6 | 7 | 42 | ||
| FG magnetic | 1 | 3 | 33 | 0 | 0 | 3 | 11 | 1 | 10 | 7 | 54 | |
| |
|
2 |
3 |
34 |
0 |
0 |
3 |
10 |
1 |
2 |
7 |
46 |
| Donor 4 | Sepharose | 1 | 1 | 17 | 1 | 2 | 0 | 0 | 1 | 1 | 3 | 20 |
| 2 | 1 | 21 | 2 | 2 | 0 | 0 | 0 | 0 | 3 | 23 | ||
| FG magnetic | 1 | 1 | 21 | 1 | 1 | 0 | 0 | 1 | 1 | 3 | 23 | |
| 2 | 1 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 23 | ||
VH, CH, VL, and CL represent variable and constant regions of the heavy chain and variable and constant regions of the light chain, respectively.